Dariana Elena Pătrîntașu
Research Subjects
Dariana Elena Pătrîntașu has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Corina Eugenia Budin
Pathophysiology Department, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Târgu Mureș, 540139 Târgu Mureș, Romania
7 shared publications - Ionuț Alexandru Rența
Pneumology Department, Clinical County Hospital Mureș, 540136 Târgu Mureș, Romania
4 shared publications - Armand Gabriel Rajnoveanu
Occupational Medicine Department, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania
3 shared publications - Edith Simona Ianoși
Pulmonology Department, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Târgu Mureș, 540139 Târgu Mureș, Romania
3 shared publications - Gheorghe-Marian Rotariu
Radiology and Medical Imaging Laboratory, Mureș County Emergency Clinical Hospital, 540136 Targu Mures, Romania
3 shared publications - Iuliu Gabriel Cocuz
Pathophysiology Department, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540142 Targu Mures, Romania
3 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (20) , 3280
Observer-Related Versus Cross-Modality Variability in Ventricular Quantification by Cardiac CT and Cardiovascular Magnetic Resonance
Background/Objectives: Ventricular measurements from cardiac computed tomography (CCT) and cardiovascular magnetic resonance (CMR) may differ due to modality-specific, physiological, or observer-dependent reasons. We compared cross-modality disagreement with intra-modality interobserver variability. Methods: Fifty-four patients with CCT and CMR examinations within 36 months were retrospectively analyzed. Left ventricular (LV) end-diastolic volume (EDV), right ventricular (RV) EDV, and LV mass were measured on the same platform; 18 underwent independent second-observer measurements. The primary metric was the standard deviation of paired differences [SD(D)], with bootstrap 95% confidence intervals (CIs). Results: In the repeat-measurement subset, cross-modality SDs were 29.78 mL, 29.19 mL, and 16.72 g for LV EDV, RV EDV, and LV mass, versus 4.83, 7.33, and 6.71 within CCT and 3.57, 3.58, and 4.11 within CMR. Cross-modality variability was 6.16, 3.98, and 2.49 times the CCT and 8.34, 8.15, and 4.07 times the CMR interobserver variability; all 95% CIs exceeded 1. Examination-interval restriction did not materially reduce dispersion, and body-surface-area indexation changed scale but not relative disagreement. Conclusions: Under routine clinical conditions, cross-modality variability in EDV and LV mass exceeded interobserver variability by 2.5- to 8.3-fold. CCT-CMR differences are unlikely to reflect observer-related post-processing variability alone, and consistent modality selection appears preferable to interchanging quantitative thresholds.
- 9 October 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (20) , 3280
Open AccessObserver-Related Versus Cross-Modality Variability in Ventricular Quantification by Cardiac CT and Cardiovascular Magnetic Resonance
Background/Objectives: Ventricular measurements from cardiac computed tomography (CCT) and cardiovascular magnetic resonance (CMR) may differ due to modality-specific, physiological, or observer-dependent reasons. We compared cross-modality disagreement with intra-modality interobserver variability. Methods: Fifty-four patients with CCT and CMR examinations within 36 months were retrospectively analyzed. Left ventricular (LV) end-diastolic volume (EDV), right ventricular (RV) EDV, and LV mass were measured on the same platform; 18 underwent independent second-observer measurements. The primary metric was the standard deviation of paired differences [SD(D)], with bootstrap 95% confidence intervals (CIs). Results: In the repeat-measurement subset, cross-modality SDs were 29.78 mL, 29.19 mL, and 16.72 g for LV EDV, RV EDV, and LV mass, versus 4.83, 7.33, and 6.71 within CCT and 3.57, 3.58, and 4.11 within CMR. Cross-modality variability was 6.16, 3.98, and 2.49 times the CCT and 8.34, 8.15, and 4.07 times the CMR interobserver variability; all 95% CIs exceeded 1. Examination-interval restriction did not materially reduce dispersion, and body-surface-area indexation changed scale but not relative disagreement. Conclusions: Under routine clinical conditions, cross-modality variability in EDV and LV mass exceeded interobserver variability by 2.5- to 8.3-fold. CCT-CMR differences are unlikely to reflect observer-related post-processing variability alone, and consistent modality selection appears preferable to interchanging quantitative thresholds.
- Open Access
- 5 August 2026
- Published by George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures in Acta Marisiensis - Seria Medica
- Vol. 72 (3) , 195-199
Functional impact of Usual Interstitial Pneumonia pattern in Interstitial Lung Diseases
Objective: To evaluate longitudinal changes in pulmonary function among patients with interstitial lung disease presenting the pattern of Usual Interstitial Pneumonia treated with antifibrotic agents. Secondary objectives involved comparing the evolution between idiopathic pulmonary fibrosis and non-IPF progressive fibrosing Interstitial Lung Diseases and assessing the prognostic value of the Gender, Age, Physiology score in relation to baseline functional parameters. Methods: A retrospective observational study was conducted between June 2021 and September 2025 at the Pneumology Clinic of Mureș County Clinical Hospital that included 15 patients. Demographic data, high-resolution Computer Tomography findings, Forced Vital Capacity, Diffusing Capacity for Carbon Monoxide, and GAP scores were analyzed before and after treatment initiation. Data was assessed using Shapiro Wilk distribution test and paired t-tests. Results: The study group consisted in 11 IPF and 4 non-IPF patients, with a mean baseline Gap score of 3.831.69. Under antifibrotic therapy, FVC showed numerical stabilization (83.50 22.09% to 94.00 16.09%; p 0.94), while DLCO suggested a non-significant, controlled decline (43.86 13.23% to 40.90 16.15%; p 0.26). IPF patients had greater baseline functional impairment and a more pronounced DLCO decline evolution. Gap score negatively correlated with baseline DLCO. Conclusions: Nintedanib was associated with clinically relevant functional stabilization in UIP-pattern ILDs. Baseline functional impairment and the GAP score were revealed to be valuable variables in terms of risk stratification. Larger prospective studies are needed to confirm long-term outcomes.
- 5 August 2026
- Published by George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures in Acta Marisiensis - Seria Medica
- Vol. 72 (3) , 195-199
Open AccessFunctional impact of Usual Interstitial Pneumonia pattern in Interstitial Lung Diseases
Objective: To evaluate longitudinal changes in pulmonary function among patients with interstitial lung disease presenting the pattern of Usual Interstitial Pneumonia treated with antifibrotic agents. Secondary objectives involved comparing the evolution between idiopathic pulmonary fibrosis and non-IPF progressive fibrosing Interstitial Lung Diseases and assessing the prognostic value of the Gender, Age, Physiology score in relation to baseline functional parameters. Methods: A retrospective observational study was conducted between June 2021 and September 2025 at the Pneumology Clinic of Mureș County Clinical Hospital that included 15 patients. Demographic data, high-resolution Computer Tomography findings, Forced Vital Capacity, Diffusing Capacity for Carbon Monoxide, and GAP scores were analyzed before and after treatment initiation. Data was assessed using Shapiro Wilk distribution test and paired t-tests. Results: The study group consisted in 11 IPF and 4 non-IPF patients, with a mean baseline Gap score of 3.831.69. Under antifibrotic therapy, FVC showed numerical stabilization (83.50 22.09% to 94.00 16.09%; p 0.94), while DLCO suggested a non-significant, controlled decline (43.86 13.23% to 40.90 16.15%; p 0.26). IPF patients had greater baseline functional impairment and a more pronounced DLCO decline evolution. Gap score negatively correlated with baseline DLCO. Conclusions: Nintedanib was associated with clinically relevant functional stabilization in UIP-pattern ILDs. Baseline functional impairment and the GAP score were revealed to be valuable variables in terms of risk stratification. Larger prospective studies are needed to confirm long-term outcomes.
- Open Access
- 10 March 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (6) , 2545
The Architecture of Deep Phenotyping in Asthma: Integrating Molecular, Metabolic, and Neuro-Hormonal Endotypes
Asthma is increasingly recognized as a heterogeneous syndrome where traditional management fails, particularly given spirometry’s limitations in assessing small airway dysfunction. This review synthesizes the transition from clinical phenotyping to deep molecular endotyping, establishing a framework for precision medicine. We highlight the insufficiency of absolute eosinophil counts, proposing eosinophil cationic protein (ECP) and eosinophil-derived neurotoxin (EDN) as superior activation metrics. Furthermore, we explore Type 2 drivers (IL-4/IL-13, periostin) and epithelial alarmins like TSLP. Beyond classical immunology, the text describes metabolic dysregulation, specifically asymmetric dimethylarginine (ADMA) in obese-asthma phenotypes where nitric oxide synthase uncoupling promotes oxidative stress. We also analyze YKL-40 and surfactant protein D (SP-D) as markers of remodeling and barrier permeability, alongside microRNAs—specifically miR-21—in corticosteroid resistance. We conclude that managing refractory asthma requires shifting from reactive symptom control to an integrated analysis of multi-omic biomarkers. Establishing this comprehensive molecular profile via specialized centers is fundamental for addressing current diagnostic limitations, selecting biological therapies, and modifying the disease trajectory through an endotype-driven strategy addressing inflammatory, metabolic, and structural pathologies.
- 10 March 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (6) , 2545
Open AccessThe Architecture of Deep Phenotyping in Asthma: Integrating Molecular, Metabolic, and Neuro-Hormonal Endotypes
Asthma is increasingly recognized as a heterogeneous syndrome where traditional management fails, particularly given spirometry’s limitations in assessing small airway dysfunction. This review synthesizes the transition from clinical phenotyping to deep molecular endotyping, establishing a framework for precision medicine. We highlight the insufficiency of absolute eosinophil counts, proposing eosinophil cationic protein (ECP) and eosinophil-derived neurotoxin (EDN) as superior activation metrics. Furthermore, we explore Type 2 drivers (IL-4/IL-13, periostin) and epithelial alarmins like TSLP. Beyond classical immunology, the text describes metabolic dysregulation, specifically asymmetric dimethylarginine (ADMA) in obese-asthma phenotypes where nitric oxide synthase uncoupling promotes oxidative stress. We also analyze YKL-40 and surfactant protein D (SP-D) as markers of remodeling and barrier permeability, alongside microRNAs—specifically miR-21—in corticosteroid resistance. We conclude that managing refractory asthma requires shifting from reactive symptom control to an integrated analysis of multi-omic biomarkers. Establishing this comprehensive molecular profile via specialized centers is fundamental for addressing current diagnostic limitations, selecting biological therapies, and modifying the disease trajectory through an endotype-driven strategy addressing inflammatory, metabolic, and structural pathologies.
- Open Access
Differential Analysis of Hemogram Parameters and Cellular Ratios in Severe Asthma Exacerbations: A Comparative Study of Eosinophilic and Non-Eosinophilic Phenotypes
Asthma exacerbations are acute worsening episodes in individuals with bronchial asthma, frequently necessitating emergency hospital care. Early differentiation between eosinophilic (≥150 eosinophils/mm3) and non-eosinophilic (3) subtypes plays a crucial role in treatment decisions and identifying patients eligible for biologic therapies. The ExBA Study explored variations in complete blood count (CBC) parameters and derived cellular ratios—namely the neutrophil-to-lymphocyte (NLR), thrombocyte-to-lymphocyte (TLR), and eosinophil-to-leukocyte ratios (ELR)—in adults hospitalized with severe asthma exacerbations. Ninety patients were enrolled and categorized into eosinophilic (n = 38) and non-eosinophilic (n = 52) groups. Significant statistical differences were observed in the neutrophil and lymphocyte levels, as well as in all three ratios. ROC analysis highlighted the ELR as the most specific indicator of the eosinophilic phenotype (specificity 100%, AUC 0.938, cut-off 0.003), whereas the NLR and TLR showed stronger associations with the non-eosinophilic group (AUC 0.733 and 0.676). No meaningful differences emerged regarding arterial blood gas levels, length of hospital stay, treatment costs, or mortality. A notable association was found between a personal or family history of atopy and the eosinophilic subtype (p = 0.0181). This study underscores the relevance of CBC-based ratios in asthma phenotyping during exacerbation events.
Open AccessDifferential Analysis of Hemogram Parameters and Cellular Ratios in Severe Asthma Exacerbations: A Comparative Study of Eosinophilic and Non-Eosinophilic Phenotypes
Asthma exacerbations are acute worsening episodes in individuals with bronchial asthma, frequently necessitating emergency hospital care. Early differentiation between eosinophilic (≥150 eosinophils/mm3) and non-eosinophilic (3) subtypes plays a crucial role in treatment decisions and identifying patients eligible for biologic therapies. The ExBA Study explored variations in complete blood count (CBC) parameters and derived cellular ratios—namely the neutrophil-to-lymphocyte (NLR), thrombocyte-to-lymphocyte (TLR), and eosinophil-to-leukocyte ratios (ELR)—in adults hospitalized with severe asthma exacerbations. Ninety patients were enrolled and categorized into eosinophilic (n = 38) and non-eosinophilic (n = 52) groups. Significant statistical differences were observed in the neutrophil and lymphocyte levels, as well as in all three ratios. ROC analysis highlighted the ELR as the most specific indicator of the eosinophilic phenotype (specificity 100%, AUC 0.938, cut-off 0.003), whereas the NLR and TLR showed stronger associations with the non-eosinophilic group (AUC 0.733 and 0.676). No meaningful differences emerged regarding arterial blood gas levels, length of hospital stay, treatment costs, or mortality. A notable association was found between a personal or family history of atopy and the eosinophilic subtype (p = 0.0181). This study underscores the relevance of CBC-based ratios in asthma phenotyping during exacerbation events.
- Open Access
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio: Side by Side with Molecular Mutations in Patients with Non-Small Cell Lung Cancer—The INOLUNG Study
Background and objective: Analysis of inflammatory biomarkers, along with the neutrophil/lymphocyte ratio (NLR) or platelet/lymphocyte ratio (PLR), supports the connection between inflammation and carcinogenesis. Methods: We conducted a retrospective observational study at the Clinical County Hospital Mureș involving patients with lung cancer. The parameters analyzed included histopathological type (NSCLC: squamous cell carcinoma or adenocarcinoma; SCLC), molecular mutations (EGFR, ALK, PD-L1), parameters from the complete blood count, inflammatory parameters, and associated comorbidities. Results: A total of 380 patients were included: 115 patients in the cancer group and 265 patients in the control group. Among patients in the lung cancer group, 88 were diagnosed with NSCLC (44 adenocarcinomas, 44 squamous cell carcinomas) and 27 with SCLC. Both NLR and PLR were significantly higher in cancer patients than in the control group (5.30 versus 2.60, p < 0.001; 217 versus 136, p < 0.001, respectively). NLR and PLR differ between men and women (p = 0.005 and p = 0.056, respectively). C-reactive protein was not correlated with either NLR (p-value: 0.0669) or PLR (p-value: 0.6733) in lung cancer patients. Conclusions: The NLR and PLR values may serve as new predictive biomarkers for the diagnosis of disease in patients with lung cancer, especially those with NSCLC.
Open AccessNeutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio: Side by Side with Molecular Mutations in Patients with Non-Small Cell Lung Cancer—The INOLUNG Study
Background and objective: Analysis of inflammatory biomarkers, along with the neutrophil/lymphocyte ratio (NLR) or platelet/lymphocyte ratio (PLR), supports the connection between inflammation and carcinogenesis. Methods: We conducted a retrospective observational study at the Clinical County Hospital Mureș involving patients with lung cancer. The parameters analyzed included histopathological type (NSCLC: squamous cell carcinoma or adenocarcinoma; SCLC), molecular mutations (EGFR, ALK, PD-L1), parameters from the complete blood count, inflammatory parameters, and associated comorbidities. Results: A total of 380 patients were included: 115 patients in the cancer group and 265 patients in the control group. Among patients in the lung cancer group, 88 were diagnosed with NSCLC (44 adenocarcinomas, 44 squamous cell carcinomas) and 27 with SCLC. Both NLR and PLR were significantly higher in cancer patients than in the control group (5.30 versus 2.60, p < 0.001; 217 versus 136, p < 0.001, respectively). NLR and PLR differ between men and women (p = 0.005 and p = 0.056, respectively). C-reactive protein was not correlated with either NLR (p-value: 0.0669) or PLR (p-value: 0.6733) in lung cancer patients. Conclusions: The NLR and PLR values may serve as new predictive biomarkers for the diagnosis of disease in patients with lung cancer, especially those with NSCLC.
- Open Access
- 6 July 2024
- Published by MDPI AG in Preprints.org
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio: Side by Side with Molecular Mutations in Patients with Non-small Cell Lung Cancer. The INOLUNG Study
Background and objective: Analysis of inflammatory biomarkers, along with the neutrophil/lymphocyte ratio (NLR) or platelets/lymphocyte ratio (PLR), supports the connection between inflammation and carcinogenesis. Methods: We conducted a retrospective observational study at the Clinical County Hospital Mureș, including patients with lung cancer. The parameters analyzed included: histopathological type (NSCLC - squamous cell carcinoma or adenocarcinoma; SCLC), molecular mutations (EGFR, ALK, PD-L1), parameters from the complete blood count, inflammatory parameters and associated comorbidities. Results: 380 patients were included: 115 patients in the cancer group and 265 patients in the control group. Among patients in the lung cancer group, 88 were diagnosed with NSCLC (44 adenocarcinomas, 44 squamous cell carcinomas) and 27 with SCLC. Both NLR and PLR were significantly higher in cancer patients than in the control group (5,30 versus 2,60, p<0,001; 217 versus 136, p< 0.001, respectively). NLR and PLR differs between men and women (p = 0.005, respectively p=0.056). C-reactive protein was not correlated with either NLR (p-value: 0.0669) or PLR (p-value: 0.6733) in lung cancer patients. Conclusion: The NLR and PLR values may serve as new predictive biomarkers for the diagnostic of disease in patients with lung cancer, especially those with NSCLC.
- 6 July 2024
- Published by MDPI AG in Preprints.org
Open AccessNeutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio: Side by Side with Molecular Mutations in Patients with Non-small Cell Lung Cancer. The INOLUNG Study
Background and objective: Analysis of inflammatory biomarkers, along with the neutrophil/lymphocyte ratio (NLR) or platelets/lymphocyte ratio (PLR), supports the connection between inflammation and carcinogenesis. Methods: We conducted a retrospective observational study at the Clinical County Hospital Mureș, including patients with lung cancer. The parameters analyzed included: histopathological type (NSCLC - squamous cell carcinoma or adenocarcinoma; SCLC), molecular mutations (EGFR, ALK, PD-L1), parameters from the complete blood count, inflammatory parameters and associated comorbidities. Results: 380 patients were included: 115 patients in the cancer group and 265 patients in the control group. Among patients in the lung cancer group, 88 were diagnosed with NSCLC (44 adenocarcinomas, 44 squamous cell carcinomas) and 27 with SCLC. Both NLR and PLR were significantly higher in cancer patients than in the control group (5,30 versus 2,60, p<0,001; 217 versus 136, p< 0.001, respectively). NLR and PLR differs between men and women (p = 0.005, respectively p=0.056). C-reactive protein was not correlated with either NLR (p-value: 0.0669) or PLR (p-value: 0.6733) in lung cancer patients. Conclusion: The NLR and PLR values may serve as new predictive biomarkers for the diagnostic of disease in patients with lung cancer, especially those with NSCLC.
- Open Access
- 28 October 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (21) , 3332
A Multidisciplinary Approach as a Goal for the Management of Complications in Systemic Scleroderma: A Literature Review and Case Scenario
Systemic sclerosis (also known as scleroderma) is a chronic fibrosing autoimmune disease with both skin and multisystem organ involvement. Scleroderma has the highest mortality among all rheumatic diseases. The pathophysiology mechanism of systemic sclerosis is a progressive self-amplifying process, which involves widespread microvascular damage, followed by a dysregulation of innate and adaptive immunity and inflammation and diffuse fibrosis of the skin and visceral organs. Fibrosis of internal organs is a hint for systemic sclerosis, moreover associated with interstitial lung disease (SSc-ILD) is a complex process. In order to correlate scientific data from the literature with clinical experience, we present the case of a 56-year-old woman who was diagnosed with systemic sclerosis 16 years ago. The association of numerous comorbidities characterized by a considerable level of seriousness characterizes this case: the highly extensive systemic damage, the cardiovascular impact of the illness, and the existence of severe pulmonary arterial hypertension. The systemic and clinical manifestations, respiratory functional tests, radiological features, and specific therapy are discussed.
- 28 October 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (21) , 3332
Open AccessA Multidisciplinary Approach as a Goal for the Management of Complications in Systemic Scleroderma: A Literature Review and Case Scenario
Systemic sclerosis (also known as scleroderma) is a chronic fibrosing autoimmune disease with both skin and multisystem organ involvement. Scleroderma has the highest mortality among all rheumatic diseases. The pathophysiology mechanism of systemic sclerosis is a progressive self-amplifying process, which involves widespread microvascular damage, followed by a dysregulation of innate and adaptive immunity and inflammation and diffuse fibrosis of the skin and visceral organs. Fibrosis of internal organs is a hint for systemic sclerosis, moreover associated with interstitial lung disease (SSc-ILD) is a complex process. In order to correlate scientific data from the literature with clinical experience, we present the case of a 56-year-old woman who was diagnosed with systemic sclerosis 16 years ago. The association of numerous comorbidities characterized by a considerable level of seriousness characterizes this case: the highly extensive systemic damage, the cardiovascular impact of the illness, and the existence of severe pulmonary arterial hypertension. The systemic and clinical manifestations, respiratory functional tests, radiological features, and specific therapy are discussed.
- Open Access
- 18 October 2023
- Published by MDPI AG in Preprints.org
Multidisciplinary Aproach: A Goal For The Management Of Complications In Systemic Scleroderma. Literature Review And Case Scenario
Systemic sclerosis (also known as scleroderma) is a chronic fibrosing autoimmune disease with both skin and multisystem organ involvement. Scleroderma has the highest mortality among all rheumatic diseases. The pathophysiology mechanism of systemic sclerosis is a progressive self-amplifying process, which implicates the widespread microvascular damage, followed by a dysregulation of innate and adaptive immunity and inflammation, and diffuse fibrosis of the skin and visceral organs. Fibrosis of internal organs is a hint for systemic sclerosis, moreover associated with interstitial lung disease (SSc-ILD) is a complex process. We report a case of a 56 years old female, diagnosed with Systemic Sclerosis 16 years ago. The systemic and clinical manifestations, respiratory functional tests, radiological aspects and specific therapy were discussed.
- 18 October 2023
- Published by MDPI AG in Preprints.org
Open AccessMultidisciplinary Aproach: A Goal For The Management Of Complications In Systemic Scleroderma. Literature Review And Case Scenario
Systemic sclerosis (also known as scleroderma) is a chronic fibrosing autoimmune disease with both skin and multisystem organ involvement. Scleroderma has the highest mortality among all rheumatic diseases. The pathophysiology mechanism of systemic sclerosis is a progressive self-amplifying process, which implicates the widespread microvascular damage, followed by a dysregulation of innate and adaptive immunity and inflammation, and diffuse fibrosis of the skin and visceral organs. Fibrosis of internal organs is a hint for systemic sclerosis, moreover associated with interstitial lung disease (SSc-ILD) is a complex process. We report a case of a 56 years old female, diagnosed with Systemic Sclerosis 16 years ago. The systemic and clinical manifestations, respiratory functional tests, radiological aspects and specific therapy were discussed.
- Open Access
- 7 August 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (8) , 1235
The Inflammatory Profile Correlates with COVID-19 Severity and Mortality in Cancer Patients
Background: The correlation of the inflammatory profile with the severity of the disease in neoplastic patients with SARS-CoV-2 infection was addressed. Methods: A database of 1537 patients hospitalized in the pneumology department was analyzed. After applying the inclusion and exclusion criteria, 83 patients (67% males, 33% females) were included. Results: Most of the analyzed patients were hospitalized with a moderate form of disease, explaining the significant percentage of 25% mortality. The frequency of the type of neoplasm was higher for lung cancer, followed by malignant colon tumor. We identified a significant association between the increased value of ferritin (p < 0.0001, OR = 22.31), fibrinogen (p = 0.009, OR = 13.41), and C-reactive protein (p = 0.01, OR = 7.65), respectively, and the level of severity of COVID-19. The results of the univariate logistic regression analysis for predicting the severity of the disease revealed that the increased values of ferritin (p = 0.001, OR = 22.31) and fibrinogen (p = 0.02, OR = 13.41) represent a risk for a serious negative prognosis of COVID-19. Conclusions: Our study demonstrated that the value of the analyzed inflammatory parameters increased in direct proportion to the severity of the disease and that higher values were associated with increased mortality in the study group.
- 7 August 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (8) , 1235
Open AccessThe Inflammatory Profile Correlates with COVID-19 Severity and Mortality in Cancer Patients
Background: The correlation of the inflammatory profile with the severity of the disease in neoplastic patients with SARS-CoV-2 infection was addressed. Methods: A database of 1537 patients hospitalized in the pneumology department was analyzed. After applying the inclusion and exclusion criteria, 83 patients (67% males, 33% females) were included. Results: Most of the analyzed patients were hospitalized with a moderate form of disease, explaining the significant percentage of 25% mortality. The frequency of the type of neoplasm was higher for lung cancer, followed by malignant colon tumor. We identified a significant association between the increased value of ferritin (p < 0.0001, OR = 22.31), fibrinogen (p = 0.009, OR = 13.41), and C-reactive protein (p = 0.01, OR = 7.65), respectively, and the level of severity of COVID-19. The results of the univariate logistic regression analysis for predicting the severity of the disease revealed that the increased values of ferritin (p = 0.001, OR = 22.31) and fibrinogen (p = 0.02, OR = 13.41) represent a risk for a serious negative prognosis of COVID-19. Conclusions: Our study demonstrated that the value of the analyzed inflammatory parameters increased in direct proportion to the severity of the disease and that higher values were associated with increased mortality in the study group.